|
Alcoholic Intoxication, Chronic
|
0.540 |
GeneticVariation
|
disease |
BEFREE |
We develop a pharmacokinetic model describing how genetic variations in ADH1B, ADH1C, ADH7, ALDH2, and TAS2R38 affect consumption behavior, and alcohol and acetaldehyde levels over time in various tissues of individuals with a particular genotype to predict their susceptibility to alcohol dependence.
|
20714161 |
2010 |
|
Alcoholic Intoxication, Chronic
|
0.540 |
Biomarker
|
disease |
PSYGENET |
We develop a pharmacokinetic model describing how genetic variations in ADH1B, ADH1C, ADH7, ALDH2, and TAS2R38 affect consumption behavior, and alcohol and acetaldehyde levels over time in various tissues of individuals with a particular genotype to predict their susceptibility to alcohol dependence.
|
20714161 |
2010 |
|
Alcoholic Intoxication, Chronic
|
0.540 |
Biomarker
|
disease |
PSYGENET |
We used family-based association methods to test for association between TAS2R38 haplotypes and alcohol dependence as well as a measure of alcohol consumption (Maxdrinks) and age of onset of drinking behaviors in a sample of families densely affected with alcoholism.
|
17250611 |
2007 |
|
Alcoholic Intoxication, Chronic
|
0.540 |
GeneticVariation
|
disease |
BEFREE |
We used family-based association methods to test for association between TAS2R38 haplotypes and alcohol dependence as well as a measure of alcohol consumption (Maxdrinks) and age of onset of drinking behaviors in a sample of families densely affected with alcoholism.
|
17250611 |
2007 |
|
Alcoholic Intoxication, Chronic
|
0.540 |
Biomarker
|
disease |
CTD_human |
We used family-based association methods to test for association between TAS2R38 haplotypes and alcohol dependence as well as a measure of alcohol consumption (Maxdrinks) and age of onset of drinking behaviors in a sample of families densely affected with alcoholism.
|
17250611 |
2007 |
|
Alcoholic Intoxication, Chronic
|
0.540 |
Biomarker
|
disease |
PSYGENET |
Implications for the genetic link between PTC taste status and alcoholism are discussed.
|
16712955 |
2006 |
|
Alcoholic Intoxication, Chronic
|
0.540 |
Biomarker
|
disease |
BEFREE |
Implications for the genetic link between PTC taste status and alcoholism are discussed.
|
16712955 |
2006 |
|
Alcoholic Intoxication, Chronic
|
0.540 |
Biomarker
|
disease |
BEFREE |
These results are inconsistent with the view that excessive use of alcohol causes the association between nontasting and alcoholism and are consistent with the view that there is a genetic association between PROP/PTC-tasting and alcoholism.
|
1641428 |
1992 |
|
Alcoholic Intoxication, Chronic
|
0.540 |
Biomarker
|
disease |
PSYGENET |
These results are inconsistent with the view that excessive use of alcohol causes the association between nontasting and alcoholism and are consistent with the view that there is a genetic association between PROP/PTC-tasting and alcoholism.
|
1641428 |
1992 |
|
Alcohol Use Disorder
|
0.300 |
Biomarker
|
disease |
CTD_human |
Functional variants in TAS2R38 and TAS2R16 influence alcohol consumption in high-risk families of African-American origin.
|
17250611 |
2007 |
|
Alcohol abuse
|
0.300 |
Biomarker
|
disease |
CTD_human |
Functional variants in TAS2R38 and TAS2R16 influence alcohol consumption in high-risk families of African-American origin.
|
17250611 |
2007 |
|
FH: Depression
|
0.300 |
Biomarker
|
phenotype |
PSYGENET |
Phenylthiocarbamide tasting and family history of depression, revisited: low rates of depression in families of supertasters.
|
15081630 |
2004 |
|
THIOUREA TASTING
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
|
|
|
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The current data suggest that PD-L1 expression in the thyroid gland might represent a marker of malignancy that correlates with PTC, but not with NIFTP.
|
31821747 |
2020 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Seventeen patients underwent a thyroid nodule FNAB (results: 12 benign, one follicular neoplasm, three suspicious for malignancy, and one papillary thyroid cancer [PTC]), from which six underwent thyroidectomy; PTC was confirmed by surgical pathology for all cases (8.5% of all nodules observed).
|
31461359 |
2020 |
|
Papillary thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Seventeen patients underwent a thyroid nodule FNAB (results: 12 benign, one follicular neoplasm, three suspicious for malignancy, and one papillary thyroid cancer [PTC]), from which six underwent thyroidectomy; PTC was confirmed by surgical pathology for all cases (8.5% of all nodules observed).
|
31461359 |
2020 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The current data suggest that PD-L1 expression in the thyroid gland might represent a marker of malignancy that correlates with PTC, but not with NIFTP.
|
31821747 |
2020 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Genetic variation in TAS2R38 bitterness taste receptor could alter the efficacy of molecular sensing, hence may be associated with cancer risk.
|
30663393 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We examined the relationship between PTC sensitivity or TAS2R38 diplotype, food intake, and cancer risk in the UK Women's Cohort Study.
|
29980925 |
2019 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Taken together, the miR-96-3p is involved in PTC metastasis and invasion by direct targeting SDHB and the downstream molecule AKT and mTOR.
|
31749660 |
2019 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Although transcervical approach for RPLN metastases of PTC provided acceptable functional and oncological outcomes, half of the patients with RPLN metastasis have had distant metastasis and/or persistent locoregional disease.
|
31004196 |
2019 |
|
Neoplasm Metastasis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
TERT promoter mutations correlated with older age (P < 0.0001), larger tumor size (P = 0.0002), oxyntic and aggressive PTC variants (P = 0.01), higher tumor stages (P < 0.0001), distant metastases (<0.0001) and disease outcome (P < 0.0001).
|
31042674 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>Methods:</b> Here, we investigated the impact of PTC-209, a small-molecule Bmi-1 inhibitor, on human cancer cell viability alone and in combination with anticancer drugs, namely, cisplatin, oxaliplatin, 5-fluorouracil, camptothecin, and Frondoside-A and its impact on cellular migration and colony growth <i>in vitro</i> and on tumor growth <i>in ovo</i>.
|
31695609 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We describe a case of papillary thyroid carcinoma with fibromatosis/fasciitis-like stroma (PTC-FLS) that contained the rare BRAF c.1799_1801delTGA (p.V600_K601delinsE) mutation, which has not previously been reported in this tumour, as well as the CTNNB1 c.133T>C (p.S45P) mutation.
|
31327063 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
TERT promoter mutations correlated with older age (P < 0.0001), larger tumor size (P = 0.0002), oxyntic and aggressive PTC variants (P = 0.01), higher tumor stages (P < 0.0001), distant metastases (<0.0001) and disease outcome (P < 0.0001).
|
31042674 |
2019 |